---
title: "Lysergide (DT120) in Generalized anxiety disorder: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Economic burden and healthcare resource utilization. Topics: Direct and indirect costs: 2022 US National Health and Wellness Survey, sponsor-funded; Healthcare resource use, adjusted: 2022 US National Health and Wellness Survey, sponsor-funded; Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded; Work productivity and activity impairment: 2022 US National Health and Wellness Survey, sponsor-funded; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Direct and indirect costs: 2022 US National Health and Wellness Survey, sponsor-funded

> “This cross-sectional study analyzed data from the 2022 US National Health and Wellness Survey (N=75,261), an online self-report survey of adults (aged ≥18) that is representative of US Census on age, sex, and race/ethnicity.”
> “Direct medical costs were calculated using 2021 Medical Expenditure Panel data for outpatient visits, hospitalizations, and emergency department visits. Indirect costs were estimated using the human capital approach.”
> “The adjusted total direct and indirect costs were $9,190 and $6,532, respectively, among no-GAD. Compared with no-GAD, the adjusted total direct costs were 1.27 and 1.96 times higher for diagnosed ($11,711) and undiagnosed GAD ($18,045), respectively (both, p<0.01); and the adjusted total indirect costs were 1.15 and 1.20 times higher for diagnosed ($7,507) and undiagnosed GAD ($7,805), respectively (both, p<0.01).”

Source: [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843)

<a id="topic-2.2.1.8.2-2"></a>

### Healthcare resource use, adjusted: 2022 US National Health and Wellness Survey, sponsor-funded

> “Outcomes included health care provider (HCP) visits, emergency room (ER) visits, and hospitalizations within the past 6 months.”
> “Diagnosed GAD had an adjusted average of 3.1 HCP visits, 0.31 ER visits, and 0.19 hospitalizations within the past 6 months.”
> “Compared with diagnosed GAD, undiagnosed GAD had significantly lower rates of HCP visits (IDR: 0.71, 95%CI: 0.66-0.77). However, undiagnosed GAD was 1.64 times more likely to have an ER visit (95%CI: 1.42-1.90) and 1.95 times more likely to have a hospitalization (95%CI: 1.59-2.40) than diagnosed GAD, suggesting significantly greater HCRU among the undiagnosed group.”
> “No-GAD had significantly lower rates of HCP (IDR: 0.64, 95%CI: 0.59-0.68) and ER (IDR: 0.84, 95%CI: 0.73-0.96) visits and similar hospitalization rates (IDR: 0.97, 95%CI: 0.80-1.19) than diagnosed GAD.”

Source: [Duong et al. (2024b)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/138043)

<a id="topic-2.2.1.8.2-3"></a>

### Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded

> “Supported by funding from MindMed, Inc.”
> “Diagnosed GAD (n=5,526) was defined as reporting either (1) experiencing anxiety symptoms and currently diagnosed with GAD, (2) screened positive with GAD (GAD-7 score ≥10), or (3) previously diagnosed with GAD and using treatment/therapy for GAD.”
> “Similarly, undiagnosed GAD participants had a greater mean number of ER visits (1.3 vs 0.5) and hospitalizations (1.2 vs 0.3) but fewer HCP visits (3.0 vs 8.7; all, p<0.001) in the past 6 months than diagnosed GAD participants”
> “The survey was distributed to a group of payers (n=20) comprised of large national payers (n=7), pharmacy benefit managers (PBM) (n=5), and regional payers (n=8) covering 130.3 million lives.”
> “60% disagreed that GAD is burdensome to employers, and 40% believed that GAD did not present a significant budgetary concern to their payer plan”
> “70% of payers believe the number of diagnosed individuals with GAD seeking reimbursement for treatment will increase in the next 3 years”

Source: [Duong et al. (2024d)](https://d1io3yog0oux5.cloudfront.net/_1e86c849bdc3b52ea5177f8157ee1069/mindmed/db/2265/21481/pdf/MNMD+AMCP+Nexus+2024+Poster.pdf)

<a id="topic-2.2.1.8.2-4"></a>

### Work productivity and activity impairment: 2022 US National Health and Wellness Survey, sponsor-funded

> “Compared with controls (8.0%, 95% confidence interval [CI]: 7.6%-8.4%), participants with severe GAD had significantly higher absenteeism (11.4%, 95%CI: 8.4%-15.5%).”
> “The severe GAD group reported the highest presenteeism (26.3%, 95%CI: 22.5%-30.7%), overall, followed by the moderate (24.1%, 95%CI: 20.8%-27.8%) and mild (22.6%, 95%CI: 20.1%-25.6%) groups, and controls had significantly lower presenteeism than the other groups (19.3%, 95%CI: 18.8%-19.7%).”
> “Similar trends by GAD symptom severity were observed for overall work productivity loss and activity impairment.”

Source: [Duong et al. (2024c)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3900/137986)

<a id="topic-2.2.1.8.2-5"></a>

### Healthcare resource use with and without co-occurring major depressive disorder: U.S. claims 2022 to 2024, sponsor-authored

> “This retrospective analysis used US claims (Komodo; 2022-2024).”
> “The index date was the first GAD or MDD encounter in 2024, and HCRU was assessed 12 months post-index, including the mean number of encounters per patient among those with ≥1 visit.”
> “Cohorts included GAD (n=991,306), MDD (n=1,436,078), and GAD+MDD (n=927,476).”
> “Medicare coverage was most common in MDD (47%), whereas commercial insurance predominated in GAD (60%).”
> “Patients with GAD+MDD had the highest overall healthcare utilization across all settings, including outpatient visits (11.8 vs 8.4 and 9.0), office visits (19.6 vs 15.1 and 15.0), emergency department visits (2.6 vs 2.1 and 2.1), and inpatient visits (3.4 vs 2.6 and 2.4) compared with GAD and MDD, respectively.”

Source: [Louie (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/healthcare-resource-utilization-in-patients-with-co-occurring-generalized-anxiety-disorder-and-major-depressive-disorder-a-real-world-claims-analysis)

<a id="topic-2.2.1.8.2-6"></a>

### U.S. health care spending on anxiety disorders, 2016

| Measure | Anxiety disorders |
| --- | --- |
| Spending rank among 154 health conditions | “21” |
| Health care spending, 2016 $Billion (95% CI) | “42.4 (37.8-47.7)” |
| Age 20 to 64 years, % of spending | “75.3” |
| Public insurance, % of spending | “49.6” |
| Private insurance, % of spending | “41.2” |
| Out-of-pocket payments, % of spending | “9.2” |
| Ambulatory care, % of spending | “55.7” |
| Inpatient care, % of spending | “7.0” |
| Prescribed pharmaceuticals, % of spending | “21.3” |

Source: [Dieleman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7054840/)

<a id="topic-2.2.1.8.2-7"></a>

### Incremental direct medical expenditures for anxiety disorders: Medical Expenditure Panel Survey 2009 and 2010

> “Data from the 2009 and 2010 Medical Expenditure Panel Survey (MEPS) were used to estimate the annual incremental healthcare expenditures associated with anxiety disorders, for the ambulatory adult population of the U.S.”
> “The annual overall healthcare expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p<0.001).”
> “Inpatient visits, prescription medications, and office-based visits together accounted for almost 93% of the overall cost.”
> “Given the prevalence of self-reported anxiety disorders in MEPS, their total direct medical expenditure is estimated at approximately $33.71 billion in 2013 US dollars”

Source: [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/)

<a id="topic-2.2.1.8.2-8"></a>

### Out-of-pocket costs for anxiety disorders by insurance type: Medical Expenditure Panel Survey 2011 to 2014

> “Using weighted nationally representative data from the 2011-2014 Medical Expenditure Panel Surveys, total OOP health care costs were assessed for all respondents who indicated that they had an anxiety disorder (N = 9985).”
> “Average annual OOP costs among individuals with anxiety was $1152.”
> “The highest OOP cost were incurred by individuals with private fee-for-service (FFS) insurance ($1356/year, 4.1% of annual income), while individuals enrolled in HMOs with dual Medicare/Medicaid had the lowest OOP cost ($129/year, 6.8% of annual income).”
> “Individuals without insurance had high OOP cost burden ($1309/year, 12.5% of annual income).”

Source: [Tucker et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29935451/)

<a id="topic-2.2.1.8.2-9"></a>

### Healthcare costs before and after starting pharmacotherapy for GAD: U.S. claims 2003 to 2007

> “Using a large US health insurance database, we identified all patients with evidence of GAD (ICD-9-CM diagnosis code 300.02) who initiated pharmacotherapy with medications commonly used to treat GAD (eg, selective serotonin reuptake inhibitors [SSRIs], venlafaxine, benzodiazepines) between 1/1/2003 and 12/31/2007.”
> “A total of 10,275 patients met all study inclusion criteria.”
> “Mean (SD) total healthcare costs increased from $4812 ($10,006) during pretreatment to $7182 ($22,041) during follow-up (p < 0.01); costs of GAD-related pharmacotherapy during follow-up were $420 ($485).”

Source: [Berger et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266199/)

<a id="topic-2.2.1.8.2-10"></a>

### Medical costs of GAD in primary care: systematic review

> “GAD patients had significantly higher median medical costs than primary care patients without GAD (US $2375 versus $1448).”
> “The mean annual medical cost of GAD was $2138 higher than for other anxiety disorders (mean $6475).”
> “GAD is associated with significant burden on patient functioning and well-being, leading to increased health care utilization and medical costs.”

Source: [Revicki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22154706/)

<a id="topic-2.2.1.8.2-11"></a>

### Cost-of-illness studies of anxiety disorders: systematic review and meta-analysis

> “We identified 13 top-down and 11 bottom-up COI studies.”
> “In top-down COI studies, direct costs of AD, on average, corresponded to 2.08% of health care costs and 0.22% of GDP, whereas indirect costs, on average, corresponded to 0.23% of GDP.”
> “Subgroup analysis revealed an increase in direct costs by 1.60 (1.16-2.22; p = 0.005) for SAD and 2.60 (2.01-3.36; p < 0.001) for GAD.”

Source: [Konnopka and König (2020)](https://pubmed.ncbi.nlm.nih.gov/31646432/)

<a id="topic-2.2.1.8.2-12"></a>

### Societal cost of anxiety disorders in the United States, 1990

> “We estimated the annual cost of anxiety disorders to be approximately $42.3 billion in 1990 in the United States, or $1542 per sufferer.”
> “Of the $256 in workplace costs per anxious worker, 88% is attributable to lost productivity while at work as opposed to absenteeism.”

Source: [Greenberg et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10453795/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
